TherapeuticsMD traded at $2.43 this Wednesday February 11th, increasing $0.05 or 2.10 percent since the previous trading session. Looking back, over the last four weeks, TherapeuticsMD gained 16.83 percent. Over the last 12 months, its price rose by 140.59 percent. Looking ahead, we forecast TherapeuticsMD to be priced at 2.14 by the end of this quarter and at 1.95 in one year, according to Trading Economics global macro models projections and analysts expectations.
TherapeuticsMD, Inc. is a women's healthcare company engaged in creating and commercializing products from pregnancy prevention through menopause. Its product pipeline includes IMVEXXY, BIJUVA, ANNOVERA, and prenatal vitamin product. The IMVEXXY (estradiol vaginal inserts) for the treatment of moderate-to-severe dyspareunia (vaginal pain associated with sexual activity), a symptom of vulvar and vaginal atrophy due to menopause. Its BIJUVA (estradiol and progesterone) capsules is a bioidentical hormone therapy combination of estradiol and progesterone in a single, oral capsule for the treatment of moderate-to-severe vasomotor symptoms due to menopause in women with a uterus. Its ANNOVERA (segesterone acetate (SA) and ethinyl estradiol (EE) vaginal system) is a one-year ring-shaped contraceptive vaginal system (CVS) and patient-controlled, procedure-free, reversible prescription contraceptive. Its prenatal vitamin products are sold under vitaMedMD and BocaGreenMD brands.